PML nuclear bodies and other trim-defined subcellular compartments

Advances in Experimental Medicine and Biology

Volumn 770, Issue , 2012, Pages 39-58

  Batty, Elizabeth C ^a   Jensen, Kirsten ^a   Freemont, Paul S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; ISOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TIF1ALPHA; REGULATOR PROTEIN; RFP PROTEIN; TRANSCRIPTION FACTOR; TRIPARTITE MOTIF PROTEIN; UNCLASSIFIED DRUG; PROTEIN;

APOPTOSIS; ARTICLE; B BOX DOMAIN; CELL COMPARTMENTALIZATION; CELL CYCLE PHASE; CELL FUNCTION; CELL INCLUSION; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHROMATIN; COILED COIL DOMAIN; HUMAN; MICROMORPHOLOGY; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA NUCLEAR BODY; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RING FINGER MOTIF; SENESCENCE ASSOCIATED NUCLEAR BODY; TRANSCRIPTION REGULATION; ANIMAL; CELL FRACTIONATION; CHEMISTRY; METABOLISM; PATHOLOGY; PROTEIN MOTIF; REVIEW;

AMINO ACID MOTIFS; ANIMALS; CELL COMPARTMENTATION; HUMANS; INTRANUCLEAR INCLUSION BODIES; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROTEINS; SUBCELLULAR FRACTIONS;

MLCS; MLOWN;

EID: 84878950860     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5398-7_4     Document Type: Article

References (126)

1. I. Reddy BA, Etkin LD, Freemont PS. A novel zinc finger coiled-coil domain in a family of nuclear proteins. Trends Biochem Sci 1992; 17(9):344-345.
2. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motiffamily identifies cell compartments. EMBO J 2001; 20(9):2140-2151.
3. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of ' single protein RING finger ' E3 ubiquitin ligases. Bioessays 2005; 27(11):1147-1157.
4. Dellaire G, Chin g RW, Dehghani H, et al. The number of PML nuclear bodie s increases in early S phase by a fission mech anism. J Ce ll Sci 2006 ; 119(Pt 6): I026-1 033.
5. Isho vAM, SotnikovAG, Negorev De t al. PML is critical forNOl Oformation and recruits the PML-interacting prot ein daxx to this nuclear structure when modified by SUMO-I . J Ce ll BioI 1999; 147(2):221-234.
6. Zhong S, Muller S, Ronche tti S, et al. Role of SUMO-I-modified PML in nucle ar body formation. Blood 2000 ; 95(9):2748-2 752.
7. Szostecki C, Guldner HH, Netter HJ, et al. Isolation and characterization of cDNA encoding a human nuclear antigen predomin antly recogni zed by autoa ntibodi es from patients with primary biliary cirrhosis. J Immunol 1990; 145(12):4338-4347.
8. Boisvert I'M, Kruhlak MJ, Box AK, et al. The transcriptio n coactivator CBP is a dynamic component of the promyeloc ytic leukemi a nucle ar body. J Cell BioI 2001; 152(5):1099-1106.
9. Li H, Leo C, Zhu J, et al. Sequestration and inhibiti on of Daxx-m ediated transcriptional repression by PML. Mol Cell Bioi 2000; 20(5): 1784-1796.
10. Alcalay M, Tomass oni L, Colombo E, et al. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell BioI 1998; 18(2) : I084-1093
11. Boddy MN, Duprez E, Borden KL, et al. Surfa ce residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodie s. J Cell Sci 1997; 110(Pt 18):2197-2205.
12. Negorev O, Maul GG. Cellular prot eins localized at and interacting within NDIO/PML nuclear bodies! PODs suggest functions of a nuclear depot. Oncogene 200 I ; 20(49):7234-7242.
13. Salomoni L, Pandolfi PI' . The role of PML in tumor suppress ion. Ce ll 2002; 108(2): 165-170.
14. Takahashi Y, Lallem and-Breitenbach V, Zhu Jet al. PML nuclear bodies and apoptosis. Oncogene 2004; 23(16):2819-2824.
15. Dellaire G, Bazett-Jones 0L . PML nuclear bodie s: dynam ic sensors of DNA damage and cellular stress. Bioessays 2004 ; 26(9) :963-9 77.
16. Fabunm i RP, Wigley WC, Thomas Pl, et al. Inter feron gamma regulates accumulation of the proteasome activator PA28 and immunoproteasom es at nuclear PML bodies. J Ce ll Sci 2001; 114(Pt 1):29-36.
17. Zhong S, Salomoni L, Pandolfi PI'. The transc ription al role of pML and the nuclear body. Nat Cell BioI 2000; 2(5): E85-90.
18. Strudwick S, Borden KL. Finding a role for pML in ApL pathogenesis: a critical asses sment of potenti al PML activiti es. Leukemia 2002; 16(10):1906-1917.
19. Sanche z-Pulido L, Valencia A, Rojas AM. Are promyeloc ytic leukaemia protein nuclear bodie s a scaffold for caspas e-2 programmed cell death? Trends Biochem Sci 200 7; 32(9):400-406.
20. Everett RD, Chelb i-Alix MK. pML and pML nuclear bodie s: impl ications in antiviral defence . Biochimie 2007;89(6-7):819-830.
21. Nisole S, Stoye Jp, Saib A. TRIM family proteins : retroviral restrict ion and antiviral defence. Nat Rev Microbiol 2005; 3(10) :799-808.
22. Freemont PS. The RING finger. A novel protein sequence motif related to the zinc finger. Ann NY Acad Sci 1993; 684:174-192.
23. Joazeiro CA, Weissman AM. RING finger protein s: mediato rs of ubiqui tin ligase activity. Cell 2000; 102(5):549-552.
24. Borden KL, Boddy MN, Lally J, et al. The solution structure of the RING finger domain from the acute promyelocytic leuka emia proto-oncoprotein PML. EMBO J 1995; 14(7):1532-1541.
25. Mu ZM, Chin KV, Liu JH, et al. pML, a growth suppressor disrup ted in acute promyeloc ytic leukemia. Mol Cell BioI 1994; 14(10):6858-6867.
26. Le XI', Yang L, Chang KS.Analys is ofthe growth and transformation suppressor domains ofpromyeloc ytic leukemia gene, pML. J BioI Chern 1996; 271(1) :130-13 5.
27. Borden KL, CampbellDwyer EJ, Salvato MS.The promyeloc ytic leukemia protein pML has apro-apoptotic activity mediated through its RING domain. FEBS Lett 1997; 418(1-2):30-34.
28. Regad T, Chelbi-Alix MK. Role and fate of'Plvll. nucle ar bodies in response to interferon and vira l infections. Oncogene 200 I ; 20(49) :72 74-7286.
29. Kentsis A, Gordon RE, Borden KL. Control ofbiochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci USA 2002; 99(24): 15404-15409 .
30. Borden KL. RING fingers and B-boxe s: zinc-binding protein-protein interac tion doma ins. Biochem Cell Bioi 1998; 76(2-3):351-358.
31. Borden KL, Lally JM, Martin SR, et al. In vivo and in vitro cha racteri zation of the BI and B2 zinc-binding domai ns from the acute promyelocytic leukemia protooncoprotein pML. Proc Natl Acad Sci USA 1996; 93(4) :1601-1606.
32. Fagioli M, Alcalay M, Tomassoni L, et al. Cooperation betw een the RING + BI-B2 and coiled-coil domain s of pML is necess ary for its effects on cell survival. Oncogene 1998; 16(22):2905-2913.
33. Lallemand-Breiten bach V, Zhu J, Puvion F, et al. Role of promyelocytic leukemia (PML) sumolation in nucle ar body formatio n, li S proteasome recru itment and As203-ind uced PML or PMLlretinoic acid receptor alpha degradation. J Exp Med 2001 ; 193(12):1361-1371.
34. Zhu J, Zhou J, Peres L, et al. A sumoylation site in PMLlRARA is essential for leukemi c transfo rmatio n. CancerCell2005; 7(2):143-153.
35. Massiah MA, Simmons BN, Short KM, et al. Solutio n structure of the RBCC/TR IM B-boxl domain of human MIDI: B-box with a RING. J Mol Bioi 2006; 358(2):532-545.
36. Grignani F, Testa U, Rogaia 0, et al. Effects on differ entiation by the promye locytic leukemia PMLI RARalpha protein depe nd on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J 1996; 15(18):4949-4958.
37. Kastner L, Perez A, Lutz Y, et al. Structure, localization and transcriptional propert ies of two classe s of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukem ia (APL) : struct ural similaritie s with a ncw family of oncoproteins. EMBO J 1992; 11(2):629-642.
38. Perez A, Kastner P, Sethi S, et al. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J 1993; 12(8):3 171-3182.
39. Fanelli M, Fantozzi A, De Luca P, et al. The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degra dation of promye locytic leukemia protein and other tripartite motif proteins by the proteasome. J Bioi Chem 2004; 279(7):5374-5379.
40. Muller S, Matunis MJ, Dejea n A. Conjugation with the ubiquitin-related modifier SUMO-I reg ulates the partitioning ofPML within the nucle us. EMBO J 1998; 17(1):61-70. 4 1
41. Jensen K, Shiels C, Frecmont PS. PML protein isoforms and the RBCC/TRIM motif Oncogene 2001; 20(49):72 23-7233
42. Tatham MH, Jaffray E, Vaughan OA, et al. Polymeric cha ins ofSUMO-2 and SUMO-3 are conj ugated to protein substrates by SAEIISAE2 and Ubc9. J BioI Chem 2001 ; 276(38):35368-3537 4
43. Fu C, Ahmed K, Ding H, et al. Stab ilization of PML nuclear loca lization by conjugation and oligome rization ofSUMO-3. Oncoge ne 2005; 24(35) :5401-5 413.
44. Kamitan i T, Kito K, Nguyen HP, et al. Identification of three major sentrinization sites in PML. J Bioi Chem 1998; 273(41):26675-26682.
45. Duprcz E, Saurin AJ, Desterro JM et al. SUMO-I modificationofthe acute promyclocytic Icukaemia protein PML: implications for nuclear localisation. J Cell Sci 1999; 112(Pt 3):381 -393 .
46. LaMorte VJ, Dyck JA, Ochs RL, et al. Local ization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci USA 1998; 95(9) :4991-4996
47. Desterro JM, Rodriguez MS, Kemp GO, et al. Identification of the enzyme req uired for activa tion of the small ubiquitin-like protein SUMO-I. J Bioi Chem 1999; 274(15):10618-10624.
48. Shen TH, Lin HK, Scagl ioni PP, et al. The mechanisms ofPML-nuclear body formation. Mol Ce ll 2006; 24(3) :331-339 .
49. Matunis MJ, Zha ng XD, Ellis NA. SUMO: the glue that binds. Dcv Cell 2006; 11(5):596-597.
50. Prudden J, Pebernard S, Raffa G, et al. SUMO-targ eted ubiquiti n ligases in genome stability. EMBO J 2007 ; 26(18):4089-4 101.
51. Sun H, Leverson JD, Hunter T. Conserve d function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J 2007 ; 26(18):4 102-41 12.
52. Koken MH, Linares-Cruz G, Quignon F, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995; 10(7):1315-1324.
53. Muratani M, Gerlic h 0, Janicki SM, et al. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus . Nat Cc ll Bioi 2002 ; 4(2): 106-110.
54. Eskiw CH, Dellai re G, Mymryk JS, et al. Size, position and dynamic behavior of PML nucle ar bodies following cell stress as a parad igm for supramolecular trafficking and assembly. J Cell Sci 2003 ; 116(Pt 21):44 55-4466.
55. Everett RD, Lomonte P, SternsdorfT, et al. Cell cycle regulation ofPML modification andNOI0 composition. J Cell Sci 1999; 112(Pt 24):458 1-4588 .
56. Dellaire G, Eskiw CH, Dehghani H, et al. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in GI. J Cell Sci 2006; 119(Pt 6): 1034-1042.
57. Luciani JJ, Depetris 0, Usson Y et al. PML nuclear bodies are highly organ ised DNA-prot ein structures with a function in heterochromatin remodell ing at the G2 phase. J Cell Sci 2006; 119(Pt 12):2518-2531.
58. Condemine W, Taka hashi Y, Le Bras M, et al. A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J Cell Sci 2007; 120(Pt 18):32 19-3227.
59. Fagioli M, Alcalay M, Pandolfi PI', et al. Alternative splicing ofPML transcripts predicts coexpre ssion of several carboxy-terminally differ ent protein isoforms. Oncogen e 1992; 7(6):1083-1091.
60. Lin HK, Bergmann S, Pando lfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature 2004; 431(7005):205-2 11.
61. Salomoni P, Bellodi C. New insights into the cytoplasmic function of PML. Histol Histopathol 2007; 22(8):937-946.
62. Henderso n BR, Eleftherio u A. A comparison of the activity, sequence specificity and CRMI-dependence of different nuclear export signals . Exp Cell Res 2000 ; 256 (I):2 13-224.
63. Condemine W, Takahashi Y, Zhu J, et al. Chara cterization of endogenous human promyelocytic leukemia isofonn s. Cancer Res 2006; 66 (12):6192-6198.
64. Xu lX, lou WX, Lin P, et al. A role for PML3 in centrosome duplication and genome stability. Mol Cell 2005; 17(5):72 1-732 .
65. Wang lG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptoti c pathways. Nat Genet 1998; 20(3) :266-272.
66. Hofmann TG, Will H. Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 2003; 10(12):1290-1299.
67. Fogal V, Gost issa M, Sandy Pet al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 2000; 19(22):6185-6195.
68. Guo A, Salomo ni P, Luo J, et al. The function of PML in p53-de pendent apoptos is. Nat Cell BioI 2000; 2 (I0):730-736.
69. de The H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation inacutepromyelocytic leukemia encodes a functionally altered RAR.Cell 1991;66(4):675-684.
70. Kakizuka A, Miller WH Jr, Umeso no K, et al. Chromosomal translocation t(l5;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66(4):663-674.
71. Pandolfi PP, Grignani F, Alcalay M, et al. Structure and origin of the acute promyelocytic leukemia myll RAR alpha eDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991; 6(7):1285-1292.
72. Goddard AD, Borrow J, Freemont PS, et al. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991; 254(5036):1371-1374.
73. Dyck JA, Maul GG, Miller WH Jr, et al. A novel macromo lecular structure is a target of the promyelocyteretinoic acid receptor oncoprotein . Cell 1994; 76(2):333-343.
74. Koken MH, Puvion-Dutilleul F, Guillemin MC, et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-revers ible fashio n. EMBO J 1994; 13(5): I073-1083.
75. Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 1994; 76(2):345-356.
76. Daniel MT, Koken M, Romag ne 0, et al. PML protein expression in hematopoietic and acute promyelocyt ic leukemia cells. Blood 1993; 82(6): 1858-1867.
77. Huang ME, Ye YC, Chen SR, et al. Use of all-tran s retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72(2):567-572.
78. Dong S, Stenoien DL, Qiu J, et al. Reduced intranuclear mobil ity of APL fusion proteins accompanies their mis localization and results in sequestration and decreased mobility of retinoid X receptor alpha. Mol Cell BioI 2004; 24(10):4465-4475.
79. Huang Y, Qiu J, Chen G, et al. Coiled-coi l domain of PML is essentia l for the aberrant dynamics of PML-RARalpha, resulting in sequestration and decreased mobility of SMRT. Biochem Biophys Res Comm un 2008; 365(2) :258-265.
80. Everett RD. Interactions between DNA viruses, NDIO and the DNA damage response. Cell Microbiol 2006; 8(3):365-374.
81. lshov AM, Maul GG. The periphery of nuclear domain 10 (NDIO) as site ofDNA virus deposition. J Cell Bioi 1996; 134(4):815-826.
82. Maul GG, Ishov AM, Everett RD. Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-I. Virology 1996; 217(1):67-75.
83. Chelb i-Alix MK, Pelicano L, Quignon F, et al. Induction of the PML protein by interferons in normal and API. cells. Leukemia 1995; 9 (12):2027-2033.
84. Lavau C, Marchio A, Fagioli Met al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995; 11(5):87 1-876 .
85. Chelbi-Alix MK, Quignon F, Pelicano L, et al. Resistance to virus infection conferred by the interferoninduced promyelocytic leukemia protein. J Virol 1998; 72(2): I043-1051.
86. Carvalho T, Seeler JS, Ohman K, et al. Targeti ng of adenovirus EIA and E4-0 RF3 proteins to nuclear matrix-assoc iated PML bodies. J Cell BioI 1995; 131(1):45-56.
87. Doucas V, Ishov AM, Romo A, et al. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev 1996; 10(2) :196-207.
88. HoppeA, Beech SJ, DimmockJ, et al. lnteractionofthe adenovirus type 5 E4 OrO protein with promyelocytic leukemia protein isofonn II is required for ND 10 disruption. J Virol 2006; 80(6):3042-3049.
89. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body compo nent TRIM5a lpha restricts HIV-I infection in Old World monkeys. Nature 2004; 427(6977):848-853.
90. Perez-Caballero O, Hatziioannou T, Yang A, et al. Human tripartite motif 5alpha domains responsib le for retrovi rus restriction activity and specificity. J Viro12005 ; 79(14):8969-8978.
91. Campbell EM, DoddingMP, YapMW, et al. TRIM5 alpha cytop lasmic bodies are highly dynamic structures. Mol Bioi Cell 2007 ; 18(6):2102-21 11.
92. Bernardi R, Scagl ioni PP, Bergmann S, et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell BioI 2004; 6(7) :665-672 .
93. Janderova-Rossmeislova L, NovakovaZ, Vlasa kova J, et al. PML protein assoc iation with spec ific nucleolar structures differs in normal, tumor and senescent human cells. J Struct BioI 2007; 159(1):56-70.
94. Kiesslich A, von Mikecz A, Hemmerich P. Cell cycle-dependent associa tion ofPML bodies with sites of active trans cription in nucle i of mammal ian cells. J Struct BioI 2002;140(1-3):167-179.
95. Everett RD, Earnshaw WC, Pluta AF, et al.A dynamic connection betwee n centromeres and NOlO proteins. J Cell Sci 1999; 112(Pt 20):3443-3454.
96. BryanTM, EnglezouA, Dalla-PozzaL, et al. Evidence for an alternative mechanism formaintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3(11) :1271-1274.
97. Dunham MA, Neumann AA, Fasching CL, et al. Telomere maintenance by recombin ation in human cells. Nat Genet 2000; 26(4):447-450.
98. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59(17):4175-4179.
99. Shiels C, Islam SA, Vatcheva R, et al. PML bodies assoc iate specifically with the MHC gene cluster in interphase nuclei . J Cell Sci 2001; 114(Pt 20):3705-3716.
100. Wang J, Shiels C, Sasieni P, et al. Promyelocytic leukemia nuclear bodies assoc iate with transcriptionally active geno mic regio ns. J Cell Bioi 2004; 164(4):515-526.
101. Hasegawa N, Iwashi ta T, Asai N, et al. A RING finger motif reg ulates transforming activity of the rfp/ret fusio n gene . Biochem Biophys Res Commun 1996; 225(2):627-63 1.
102. Klugbauer S, Rabes HM. The transcription coactivator IITIFI and a related protein are fused to the RET receptor tyrosi ne kinase in childhood papillary thyroid carcinomas. Oncogene 1999; 18(30) :4388-4393.
103. Le Douar in B, Zeche l C, Garn ier JM, et al. The N-terminal part of Tl FI, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 1995; 14(9):2020-2033.
104. Zhong S, Delva L, Rachez C, et al. A I{A-depende nt, tumo ur-growth suppressiv e transcription complex is the target oft he PML-RARa lpha and T18 oncoproteins. Nat Genet 1999; 23(3):287-295 .
105. Seeler JS, Marchio A, Losson R, et al. Common properties of nuclear body protein SP IOO and TIFlalpha chromatin factor: role ofSUMO modification. Mol Cell BioI 200 I ; 21(I 0):3314-3324.
106. Le Douar in B, Nielsen AL, Garnier JM, et al. A possible involvement ofTlFI alpha and TIFI beta in the epigenetic control oftranscription by nuclear receptors . EMBO J 1996; 15(23):6701-6715.
107. Peng H, Feldman I, Rauscher FJ 3rd. Hetero-oligomerization among the TlF family of RBCC/TRIM domain-containing nuclearcofactors: a potentialmechanism forregulating the switch between coactivation and corepression . J Mol BioI 2002; 320(3):629-644.
108. Yondola MA, Hearing P.The adenovi rus E4ORF3 protein binds and reorganizes theTRIM family member transcriptional intermediary factor I alpha. J Viro12007; 81(8):4264-4271.
109. Kikuchi T, Taka hashi M, Ueda Ret al. Nuclear localization of antigens detected by a monoclonal antibody agai nst a synthetic peptide of rfp finger protein. Hybridoma 1990; 9(2): 189-200.
110. Tezel G, Nagasaka T, Iwahas hi N, et al. Different nuclear/cy toplasmic distributions of RET finger protein in different cell types. Patholl nt 1999; 49(10):881-886.
111. Shimono Y, Murakami II, Hasegawa Y, et al. RET finger protein is a transcriptional repressor and interacts withenhancer ofpolycomb that has dual transcriptiona l functions. J BioIChem2000;275(50):39411-39419.
112. Matsuura T, Shimono Y, Kawai K, et al. PIAS proteins are involved in the SUMO-I modification, intracellular trans locat ion and transcriptional repressive activity of RET finger protein. Exp Cell Res 2005; 308 (1):65-77.
113. Harbe rs M, Nomura T, Ohno S, et al. Intracellul ar localizatio n of the Ret finger protein depends on a functional nuclear export signal and protein kinaseC activation. J BioiChern200 I; 276(51):48596 -48607 .
114. Schmidt 0, Muller S. PIAS/SUMO: new partners in transc riptional regulation. Cell Mol Life Sci 2003 ; 60 (12):256 1-2574.
115. Cao T, Borden KL, Freemo nt PS, et al. lnvolvement of the rfp tripartite motif in protein-protein interactio ns and subce llular distribu tion. J Cell Sci 1997; 110(Pt 14):1563-1571.
116. Cao T, Duprez E, Borden KL, et al. Ret finger protein is a normal component ofPML nuclear bodies and interacts directly with PML. J Cell Sci 1998; 111(Pt 10):1319-1329.
117. Dho SH, Kwon KS. The Ret finger protein induces apoptosis via its RING finger-B box-coiled-coil motif. J Bioi Chern 2003; 278(34):31902-3 1908.
118. Morr is-Des bois C, Bochard V, Reynaud C, et al. Interaction between the Ret finger protein and the Int-6 gene product and colocalisation into nuclear bod ies. J Cell Sci 1999; I 12(Pt 19):3331-3342.
119. Shyu HW, Hsu SH, Hsieh-L i HM, et al. A novel member ofthe RBCC family, Trif, expresse d specifically in the spermatids of mouse testis. Mech Dev 200 I; I08 (1-2) :2 13-2 16.
120. Shyu HW, Hsu SH, Hsieh-L i HM, et al. Forced expression of RNF36 induces cell apoptosis. Exp Cell Res 2003; 287(2):30 1-313 .
121. Bienz M. The PHD finger, a nucle ar protein-interactio n domain. Trends Biochem Sci 2006; 3 1(I) :35-40.
122. Short KM, Cox TC. Subclassification of the RBCCIT RIM superfami ly reveals a nove l motif necessary for microtubule binding. J Bioi Chern 2006; 28 1(13):8970-8980.
123. Rhodes DA, dc Bono 13, Trowsdale J. Relationship between SPRY and 1330.2 protein domains. Evo lution ofa component of immune de fence? Immu nology 2005; 116(4):41 1-41 7.
124. Avela K, Lipsane n-Nyman M, Idan heimo N, et al. Gene encoding a new RlNG-13-box-Coiled-coil protein is mutated in mulibrey nanism. Nat Genet 2000; 25(3):298-301.
125. Kall ijarvi J, Avela K, Lipsanen-Nyman M, et al. The TRIM37 ge ne encodes a pero xi somal RING-B-box-coi led-coi l protein : classification ofmulibrey nanism as a new peroxisomal diso rder. Am J Hum Genet 2002 ; 70(5) :1215 -1228.
126. Kallijarvi J, Lahtinen U, Hamalainen Ret al. TRIM37 defective in mulibrey nanism is a novel RING finger ubiquitin E3 ligase . Exp Cc ll Rcs 2005 ; 308(1) :146-155.